Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy

References

• Hirte H, Poon R, Yao X, et al. Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Crit Rev Oncol Hematol. 2021;162:103324. doi: 10.1016/j.critrevonc.2021.103324
   PubMed Web of Science ®Google Scholar
• Alves RC, Fernandes RP, Eloy JO, et al. Characteristics, properties and analytical methods of paclitaxel: a review. Crit Rev Anal Chem. 2018;48(2):110–118. doi: 10.1080/10408347.2017.1416283
   PubMed Web of Science ®Google Scholar
• Sendo T, Sakai N, Itoh Y, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol. 2005;56(1):91–96. doi: 10.1007/s00280-004-0924-9
   PubMed Web of Science ®Google Scholar
• Yanaranop M, Chaithongwongwatthana S. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: a double-blind randomized controlled trial. Asia Pac J Clin Oncol. 2016;12(3):289–299. doi: 10.1111/ajco.12495
   PubMed Web of Science ®Google Scholar
• Dubinsky S, Patel D, Wang X, et al. Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis. Support Care Cancer. 2022;30(7):5627–5644. doi: 10.1007/s00520-022-06891-0
   PubMed Web of Science ®Google Scholar
• Noetzlin S, Breville G, Seebach JD, et al. Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach. Swiss Med Wkly. 2022;152(102):w30088. doi: 10.4414/SMW.2022.w30088
   PubMedGoogle Scholar
• Mayayo-Peralta I, Zwart W, Prekovic S. Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene? Endocr Relat Cancer. 2021;28(6):R157–R171. doi: 10.1530/ERC-20-0489
   PubMed Web of Science ®Google Scholar
• Bakour N, Moriarty F, Moore G, et al. Prognostic significance of glucocorticoid receptor expression in cancer: a systematic review and meta-analysis. Cancers (Basel). 2021;13(7):1649. doi: 10.3390/cancers13071649
   PubMed Web of Science ®Google Scholar
• Melhem A, Yamada SD, Fleming GF, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009;15(9):3196–3204. doi: 10.1158/1078-0432.CCR-08-2131
   PubMed Web of Science ®Google Scholar
• Yin L, Fang F, Song X, et al. The pro-adhesive and pro-survival effects of glucocorticoid in human ovarian cancer cells. J Mol Endocrinol. 2016;57(1):61–72. doi: 10.1530/JME-15-0142
   PubMed Web of Science ®Google Scholar
• Karvonen H, Arjama M, Kaleva L, et al. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death Dis. 2020;11(9):790. doi: 10.1038/s41419-020-03009-4
   PubMed Web of Science ®Google Scholar
• Munster PN, Greenstein AE, Fleming GF, et al. Overcoming taxane resistance: preclinical and phase 1 studies of relacorilant, a selective glucocorticoid receptor modulator, with nab-paclitaxel in solid tumors. Clin Cancer Res. 2022;28(15):3214–3224. doi: 10.1158/1078-0432.CCR-21-4363
   PubMed Web of Science ®Google Scholar
• Lansinger OM, Biedermann S, He Z, et al. Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions. J Clin Oncol. 2021;39(32):3583–3590. doi: 10.1200/JCO.21.01200
   PubMed Web of Science ®Google Scholar
• Berek JS, Kehoe ST, Kumar L, et al. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obst. 2018;143(S2):59–78. doi: 10.1002/ijgo.12614
   PubMedGoogle Scholar
• Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynecol Obst. 2018;143(S2):37–50. doi: 10.1002/ijgo.12612
   PubMedGoogle Scholar
• Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri. Int J Gynecol Obst. 2018;143(S2):22–36. doi: 10.1002/ijgo.12611
   PubMedGoogle Scholar
• Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049–1060. doi: 10.2307/2531734
   PubMed Web of Science ®Google Scholar
• Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allerg Immunol. 2015;49(2):177–191. doi: 10.1007/s12016-014-8416-0
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18(1):102–105. doi: 10.1200/JCO.2000.18.1.102
   PubMed Web of Science ®Google Scholar
• Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol. 2002;84(3):420–425. doi: 10.1006/gyno.2001.6546
   PubMed Web of Science ®Google Scholar
• O’Cathail SM, Shaboodien R, Mahmoud S, et al. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies. Int J Gynecol Cancer. 2013;23(7):1318–1325. doi: 10.1097/IGC.0b013e31829f1799
   PubMed Web of Science ®Google Scholar
• Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41(5):418–424. doi: 10.1080/028418602320404998
   PubMed Web of Science ®Google Scholar
• Köppler H, Heymanns J, Weide R. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions. Onkologie. 2001;24(3):283–285. doi: 10.1159/000055093
   PubMedGoogle Scholar
• Bookman MA, Kloth DD, Kover PE, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol. 1997;8(6):611–614. doi: 10.1023/A:1008207025430
   PubMed Web of Science ®Google Scholar
• Chen FC, Wang LH, Zheng XY, et al. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions. Oncotarget. 2017;8(12):19236–19243. doi: 10.18632/oncotarget.13705
   PubMedGoogle Scholar
• Cox JM, van Doorn L, Malmberg R, et al. The added value of H2 antagonists in premedication regimens during paclitaxel treatment. Br J Cancer. 2021;124(10):1647–1652. doi: 10.1038/s41416-021-01313-0
   PubMed Web of Science ®Google Scholar
• Foreman E, Polwart C, Walker A, et al. Histamine-2 (H 2) antagonists can be safely removed from standard paclitaxel premedication regimens. Brit J Clin Pharma. 2022;88(9):4191–4198. doi: 10.1111/bcp.15363
   PubMed Web of Science ®Google Scholar
• Haine AI, Notenboom C, Tan LVP, et al. Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study. Pharmacol Res Perspect. 2022;10(4):e00985. doi: 10.1002/prp2.985
   PubMed Web of Science ®Google Scholar
• Huntjens DW, Vanhommerig JW, van de Veen W, et al. Exclusion of ranitidine from premedication regimens during paclitaxel treatment. JAMA Oncol. 2023;10(1):131. doi: 10.1001/jamaoncol.2023.4821
   Web of Science ®Google Scholar
• Montero Pérez O, Martinez Benavides J, González Fernandez T, et al. Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study. Expert Rev Clin Pharmacol. 2023;16(9):877–883. doi: 10.1080/17512433.2023.2238596
   PubMedGoogle Scholar
• Chen W, Mempel M, Schober W, et al. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy. 2008;63(11):1418–1427. doi: 10.1111/j.1398-9995.2008.01880.x
   PubMed Web of Science ®Google Scholar
• De Martinis M, Sirufo MM, Suppa M, et al. Sex and gender aspects for patient stratification in allergy prevention and treatment. Int J Mol Sci. 2020;21(4):1535. doi: 10.3390/ijms21041535
   PubMed Web of Science ®Google Scholar
• Goromaru T, Itoh Y, Sendo T, et al. Ovariectomy aggravates hypersensitivity reactions to paclitaxel in rats. Cancer Biol Ther. 2005;4(2):225–230. doi: 10.4161/cbt.4.2.1475
   PubMed Web of Science ®Google Scholar